By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DiagnoCure Inc. 

2050 Boulevard, Rene-Levesque Ouest, 6th Floor

Sainte-Foy  Quebec  G1V 2K8  Canada
Phone: 418-527-6100 Fax: 418-527-0240





Gen-Probe Incorporated (Acquired by Hologic)  In November 2003, Gen-Probe signed a license and collaboration agreement with DiagnoCure under which the companies are developing, and Gen-Probe will market, an innovative urine test to detect a new, highly specific genetic marker for prostate cancer called PCA3.

Company News
DiagnoCure (CUR) Announces Third Quarter 2015 Results 9/11/2015 7:20:22 AM
DiagnoCure (CUR) Announces Second Quarter 2015 Results And Restructures Its Board Of Directors 6/12/2015 7:21:48 AM
DiagnoCure (CUR)'s New Prostate Cancer Multimarker Urine Test Featured At A Recent Press Event Of The American Urological Association 5/21/2015 7:40:22 AM
DiagnoCure (CUR) Announces Results Of Its Annual And General Meeting Of Shareholders 5/1/2015 7:43:35 AM
Cash-Strapped DiagnoCure (CUR) Permanently Lays Off Undisclosed Number of Workers 4/24/2015 6:35:07 AM
DiagnoCure (CUR) Announces First Quarter 2015 Results 3/6/2015 6:52:35 AM
DiagnoCure (CUR) Announces Fourth Quarter 2014 And Year-End Results 1/23/2015 10:43:27 AM
DiagnoCure (CUR) Reports On Corporate Initiatives For 2014 10/31/2014 8:11:05 AM
DiagnoCure (CUR) Announces Results For Third Quarter Of 2014 9/12/2014 8:58:15 AM
Shuwen Biotech And DiagnoCure (CUR) Sign Exclusive License And Collaboration Agreement For Commercializing Previstage™ GCC Colorectal Cancer Staging Test In China 6/6/2014 10:51:37 AM